CancerCCC-CancerNCT07733973
Effectiveness, Acceptability and Feasibility of a Communication and Care Coordinator (CCC) Model in Facilitating Serious Illness Communication (SIC) and Care in Patients With Cancer
A study testing CCC Intervention in people with Cancer, run by National Cancer Centre, Singapore at 1 site in Singapore.
Trial summary
The goal of this clinical trial is to evaluate the communication and care coordinator (CCC) model in a national cancer institute and assess the utility of the model in facilitating serious illness communication (SIC) and care for patients with cancer. Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- Cancer
- What is being tested?
- CCC Intervention
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 560 participants
- Where
- 1 siteSingapore
- Study dates
- 1 Aug 2026to 30 Jun 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient Participants
- Aged 21 and above
- Diagnosed with (a) advanced cancer (stage 3 or 4) or (b) non-advanced cancer, but at high risk of recurrence
- Able to speak English or Chinese, irrespective of race
- Clinicians
- Oncologists who are at least of designation of associate consultant and above in NCCS
Who cannot join
- Patient Participants
- Confused/not able to sign informed consent
- Diagnosed with untreated hearing or visual loss or psychiatric illness
- Clinicians
- Overseas/not practising in Singapore for a significant amount of time
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Benton PT TAM, MSc contact
Singapore1 site
National Cancer Center, Singapore
Singapore, 168583
Shirlyn NEO Hui Shan, MD, PhD
63065838, shirlyn.neo.h.s@singhealth.com.sg
About this study
Official title: Evaluating the Effectiveness, Acceptability and Feasibility of a Communication and Care Coordinator (CCC) Model in Facilitating Serious Illness Communication (SIC) and Care in Patients With Cancer
The goal of this clinical trial is to evaluate the communication and care coordinator (CCC) model in a national cancer institute and assess the utility of the model in facilitating serious illness communication (SIC) and care for patients with cancer.
The study aims are:
Read more
- To assess the effectiveness of the CCC model in improving patient outcomes.
- To assess the effectiveness of the CCC model in increasing rates of SIC and advance care planning (ACP) record documentation.
- To assess the acceptability of the CCC model to patients and clinicians.
- To evaluate the feasibility of implementing a CCC model in oncology care.
Researchers will compare results from the CCC intervention arm and usual care arm, to see if the CCC model can help improve patient outcomes and facilitate SIC between patients and clinicians.
Patient participants will:
- Follow the assignment of their clinician, who will be assigned randomly to either the usual care group or the intervention group.
- Be assigned a CCC and receive 6 CCC sessions over the course of 3 months (if assigned to CCC intervention arm).
- Complete 3 study assessment visits at baseline, Week 6, and 3 months
- Be invited to a one-time interview to share their study experience (optional, if selected and if in CCC intervention arm).
Read the detailed description
Timely SIC may facilitate earlier preferred plan of care documentation and improve patients' sense of peacefulness, hopefulness, and connectedness with their clinicians. The primary goal of the study is to evaluate the CCC model in a national cancer institute and assess the utility of the model in facilitating SIC and care for patients with cancer through a stepped wedge cluster randomized trial. This approach delivers crucial, empirical insights into how SIC can be efficiently and effectively delivered and potentially allow larger scale implementation and dissemination of the CCC model in Singapore, as an effective model for delivering patient support and facilitating patient-clinician communication in patients with advanced cancer.
- Conditions
- Cancer
- Being tested
- CCC Intervention
- Keywords
- Communication and Care Coordinators, Serious Illness Communication, Healthcare Communication, Cancer Care, Oncology
- Medical subject headings
- Neoplasms, Communication
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CCC InterventionOther
CCC sessions will be on exploring participant's illness journey thus far, their concerns, values and priorities.
| Study group | Role | What they receive |
|---|---|---|
| CCC Intervention Arm | Experimental | Each participant will be assigned a CCC and receive 6 CCC sessions over the course of 3 months. Receives: Other: CCC Intervention |
| Usual Care Arm | No intervention | Each participant will continue to be followed by the oncologist and receive usual care but will not receive CCC intervention. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Communication Quality
Feeling Heard and Understood Survey (FHU) is a validated 4-item scale that has been used in palliative care to measure effectiveness of the SIC conversations and the value of the therapeutic relationship between the care team and the patient. The lowest possible score is 0 and the highest possible score is 16, with a higher score indicating that the care team listens well, respects patient's needs, and provides clear communication.
Measured: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Quality of Life per FACT-G7
Functional Assessment of Cancer Therapy-General-7 Item version (FACT-G7) is a 7-item questionnaire designed to quickly and effectively capture the most relevant issues to cancer. FACT-G7 scores could potentially range from 0-28, with a higher score indicating a better quality of life.
Measured: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Health Utility
EuroQOL Group 5-Dimension (EQ-5D-5L) contains a 5-item descriptive system measuring 5 dimensions: mobility, self-care, usual activities, pain/ discomfort, anxiety/ depression; a visual analogue scale (VAS) measuring overall health status. EQ-5D Index Value (Utility Score) ranges from 0 to 1.0 with higher value indicating better health-related quality of life. The VAS ranges from 0 to 100, with higher scores reflecting better self-rated health.
Measured: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Spiritual Well-Being
Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale (FACIT-Sp-12) is a validated 12-item survey that is commonly used in the palliative care setting. It has 3 subscales (meaning, peace and faith). Scores in each subscale can potentially range from 0-16 and the total scores can range from 0-48. A higher score indicates greater spiritual well-being, better ability to find purpose in life and drawing comfort from spiritual resources.
Measured: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Healthcare Utilization - Rate of Unplanned Acute Hospital Utilization
The rate of unplanned acute hospital utilization through the emergency department during the study will be collected.
Measured: From Study Enrolment to 3 months Post Enrolment.
Healthcare utilization - Length of hospital stay
Data on the length of stay in hospital (bed days) will be collected.
Measured: From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Hospital Bill
Data on hospital bill size will be collected.
Measured: From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Chemotherapy usage (type)
Data on the type of chemotherapy used will be collected.
Measured: From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Chemotherapy usage (line)
Data on the line of chemotherapy (first, second or third or subsequent (fourth and onwards)) will be collected.
Measured: From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Intensive care unit visit
Data on the number of intensive care unit visits will be collected.
Measured: From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Length of intensive care unit visit
Data on the length of intensive care unit visits will be collected.
Measured: From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Location of death
Data on the location of death will be collected.
Measured: From Study Enrolment until Date of Death, up to 3 years.
Secondary outcomes (6)
Acceptability - Satisfaction
Client satisfaction survey is a 4-item, 4-point scale survey in which patients provide ratings on their satisfaction with the intervention, and their views on its relevance, timeliness, and impact. It has been validated in research studies in the outpatient setting around mental health support. Score can range from 4-16, with a higher score indicating greater client satisfaction.
Measured: 3 months Post Enrolment.
Feasibility - Approach-to-Enrolment Rates
Approach-to-enrolment rates - where feasibility is defined that at least 60% of those patients approached could be enrolled into the study.
Measured: From Commencement of Study Recruitment till the End of Recruitment, up to 24 months.
Feasibility - Patient Retention Rate
Patient retention rate - where feasibility is defined that at least 80% of enrolled patients will be able to participate in the study for the planned study duration (3 months).
Measured: Baseline through Study Completion, estimated as up to 3 years.
Effectiveness - SIC and ACP documentation
The number of SIC and ACP documentation per clinician per enrolled patient during the study duration will be tracked during the intervention period(s) and during the control period(s). Clinical notes will also be read to evaluate if there was relevant documentation by clinician on SIC related issues.
Measured: From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years
Effectiveness - Time spent
Time spent by CCC in this model and estimated time spent by clinicians on SICs will be collected.
Measured: From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years
Acceptability - Clinician experience
Clinicians will be surveyed using a modified version of the Clinician Experience Survey (CES). The original CES was developed by Ariadne Labs for the purposes of assessing clinicians perceived feasibility and barriers in engaging patients in SIC. The researchers will modify the CES to form a 4-item scale (score range 4-16), with a higher score indicating greater clinicians' satisfaction with the CCC intervention.
Measured: At end of intervention period (28th month).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jul 2026
- Study start1 Aug 2026 (estimated)
- Primary completion30 Jun 2028 (estimated)
- Study completion30 Jun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (37)Papers the sponsor has linked to this study.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study will employ a stepped wedge cluster randomized trial design.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 560 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Cancer Centre, Singapore
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Shirlyn NEO Hui Shan, MD, PhD, Study chair, National Cancer Centre, Singapore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07733973
- Sponsor's protocol ID
- 2026-1239
- Acronym
- CCC-Cancer
- Status last verified
- Jul 2026
- First submitted
- 21 Jul 2026
- Last updated
- 29 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Bernacki RE, Block SD; American College of Physicians High Value Care Task Force. Communication about serious illness care goals: a review and synthesis of best practices. JAMA Intern Med. 2014 Dec;174(12):1994-2003. doi: 10.1001/jamainternmed.2014.5271.
PubMed 25330167Nikbakhsh N, Moudi S, Abbasian S, Khafri S. Prevalence of depression and anxiety among cancer patients. Caspian J Intern Med. 2014 Summer;5(3):167-70.
PubMed 25202445Kumar P, Wixon-Genack J, Kavanagh J, Sanders JJ, Paladino J, O'Connor NR. Serious Illness Conversations With Outpatient Oncology Clinicians: Understanding the Patient Experience. JCO Oncol Pract. 2020 Dec;16(12):e1507-e1515. doi: 10.1200/JOP.19.00765. Epub 2020 Aug 4.
PubMed 32749931Geerse OP, Lamas DJ, Sanders JJ, Paladino J, Kavanagh J, Henrich NJ, Berendsen AJ, Hiltermann TJN, Fromme EK, Bernacki RE, Block SD. A Qualitative Study of Serious Illness Conversations in Patients with Advanced Cancer. J Palliat Med. 2019 Jul;22(7):773-781. doi: 10.1089/jpm.2018.0487. Epub 2019 Feb 6.
PubMed 30724693Paladino J, Koritsanszky L, Nisotel L, Neville BA, Miller K, Sanders J, Benjamin E, Fromme E, Block S, Bernacki R. Patient and clinician experience of a serious illness conversation guide in oncology: A descriptive analysis. Cancer Med. 2020 Jul;9(13):4550-4560. doi: 10.1002/cam4.3102. Epub 2020 May 4.
PubMed 32363775Baxter R, Fromme EK, Sandgren A. Patient Identification for Serious Illness Conversations: A Scoping Review. Int J Environ Res Public Health. 2022 Mar 31;19(7):4162. doi: 10.3390/ijerph19074162.
PubMed 35409844Sudore RL, Fried TR. Redefining the "planning" in advance care planning: preparing for end-of-life decision making. Ann Intern Med. 2010 Aug 17;153(4):256-61. doi: 10.7326/0003-4819-153-4-201008170-00008.
PubMed 20713793Agency for integrated care. Advance care planning. Accessed via: aic.sg/Care-Services/Advance-Care-Planning-ACP. Last accessed on February 6th 2026.
Epstein AS, Riley M, Nelson JE, Bernal C, Martin S, Xiao H. Goals of care documentation by medical oncologists and oncology patient end-of-life care outcomes. Cancer. 2022 Sep 15;128(18):3400-3407. doi: 10.1002/cncr.34400. Epub 2022 Jul 22.
PubMed 35866716Karim S, Levine O, Simon J. The Serious Illness Care Program in Oncology: Evidence, Real-World Implementation and Ongoing Barriers. Curr Oncol. 2022 Mar 2;29(3):1527-1536. doi: 10.3390/curroncol29030128.
PubMed 35323328Malhotra C, Chaudhry I. Barriers to advance care planning among patients with advanced serious illnesses: A national survey of health-care professionals in Singapore. Palliat Support Care. 2024 Oct;22(5):978-985. doi: 10.1017/S1478951523000214.
PubMed 37005352Ahluwalia SC, Levin JR, Lorenz KA, Gordon HS. Missed opportunities for advance care planning communication during outpatient clinic visits. J Gen Intern Med. 2012 Apr;27(4):445-51. doi: 10.1007/s11606-011-1917-0. Epub 2011 Oct 25.
PubMed 22038469Shilling DM, Manz CR, Strand JJ, Patel MI. Let Us Have the Conversation: Serious Illness Communication in Oncology: Definitions, Barriers, and Successful Approaches. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e431352. doi: 10.1200/EDBK_431352.
PubMed 38788187Nagelschmidt K, Leppin N, Seifart C, Rief W, von Blanckenburg P. Systematic mixed-method review of barriers to end-of-life communication in the family context. BMJ Support Palliat Care. 2021 Sep;11(3):253-263. doi: 10.1136/bmjspcare-2020-002219. Epub 2020 Aug 27.
PubMed 32855230Hanley S, Cotner CE, Fenton A, Wright AA, Manz CR. Barriers to Serious Illness Conversations Among Patients with Advanced Cancer: A Qualitative Study. J Pain Symptom Manage. 2025 Feb;69(2):183-189.e4. doi: 10.1016/j.jpainsymman.2024.10.034. Epub 2024 Nov 7.
PubMed 39515596
Study at a glance
From the registry record, last updated by the sponsor on 29 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating the Effectiveness, Acceptability and Feasibility of a Communication and Care Coordinator (CCC) Model in Facilitating Serious Illness Communication (SIC) and Care in Patients With Cancer
- ClinicalTrials.gov ID
- NCT07733973
- Acronym / sponsor ID
- CCC-Cancer / 2026-1239
- Conditions
- Cancer
- Keywords
- Communication and Care Coordinators, Serious Illness Communication, Healthcare Communication, Cancer Care, Oncology
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 560 participants (estimated)
- Lead sponsor
- National Cancer Centre, SingaporeUniversity, hospital or other
- Study start
- 1 Aug 2026 (estimated)
- Primary completion
- 30 Jun 2028 (estimated)
- Study completion
- 30 Jun 2029 (estimated)
- First posted
- 29 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate the communication and care coordinator (CCC) model in a national cancer institute and assess the utility of the model in facilitating serious illness communication (SIC) and care for patients with cancer.
The study aims are:
- To assess the effectiveness of the CCC model in improving patient outcomes.
- To assess the effectiveness of the CCC model in increasing rates of SIC and advance care planning (ACP) record documentation.
- To assess the acceptability of the CCC model to patients and clinicians.
- To evaluate the feasibility of implementing a CCC model in oncology care.
Researchers will compare results from the CCC intervention arm and usual care arm, to see if the CCC model can help improve patient outcomes and facilitate SIC between patients and clinicians.
Patient participants will:
- Follow the assignment of their clinician, who will be assigned randomly to either the usual care group or the intervention group.
- Be assigned a CCC and receive 6 CCC sessions over the course of 3 months (if assigned to CCC intervention arm).
- Complete 3 study assessment visits at baseline, Week 6, and 3 months
- Be invited to a one-time interview to share their study experience (optional, if selected and if in CCC intervention arm).
Detailed description
Timely SIC may facilitate earlier preferred plan of care documentation and improve patients' sense of peacefulness, hopefulness, and connectedness with their clinicians. The primary goal of the study is to evaluate the CCC model in a national cancer institute and assess the utility of the model in facilitating SIC and care for patients with cancer through a stepped wedge cluster randomized trial. This approach delivers crucial, empirical insights into how SIC can be efficiently and effectively delivered and potentially allow larger scale implementation and dissemination of the CCC model in Singapore, as an effective model for delivering patient support and facilitating patient-clinician communication in patients with advanced cancer.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- This study will employ a stepped wedge cluster randomized trial design.
| Arm | Type | Receives |
|---|---|---|
| CCC Intervention Arm | Experimental | Other: CCC InterventionEach participant will be assigned a CCC and receive 6 CCC sessions over the course of 3 months. |
| Usual Care Arm | No intervention | –Each participant will continue to be followed by the oncologist and receive usual care but will not receive CCC intervention. |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Patient Participants
- Aged 21 and above
- Diagnosed with (a) advanced cancer (stage 3 or 4) or (b) non-advanced cancer, but at high risk of recurrence
- Able to speak English or Chinese, irrespective of race
- Clinicians
Key exclusion criteria (5 listed)
- Patient Participants
- Confused/not able to sign informed consent
- Diagnosed with untreated hearing or visual loss or psychiatric illness
- Clinicians
- Overseas/not practising in Singapore for a significant amount of time
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CCC InterventionCCC sessions will be on exploring participant's illness journey thus far, their concerns, values and priorities. | Other | CCC Intervention Arm |
Primary outcome
Communication Quality
Time frame: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Feeling Heard and Understood Survey (FHU) is a validated 4-item scale that has been used in palliative care to measure effectiveness of the SIC conversations and the value of the therapeutic relationship between the care team and the patient. The lowest possible score is 0 and the highest possible score is 16, with a higher score indicating that the care team listens well, respects patient's needs, and provides clear communication.
Quality of Life per FACT-G7
Time frame: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Functional Assessment of Cancer Therapy-General-7 Item version (FACT-G7) is a 7-item questionnaire designed to quickly and effectively capture the most relevant issues to cancer. FACT-G7 scores could potentially range from 0-28, with a higher score indicating a better quality of life.
Health Utility
Time frame: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
EuroQOL Group 5-Dimension (EQ-5D-5L) contains a 5-item descriptive system measuring 5 dimensions: mobility, self-care, usual activities, pain/ discomfort, anxiety/ depression; a visual analogue scale (VAS) measuring overall health status. EQ-5D Index Value (Utility Score) ranges from 0 to 1.0 with higher value indicating better health-related quality of life. The VAS ranges from 0 to 100, with higher scores reflecting better self-rated health.
Spiritual Well-Being
Time frame: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale (FACIT-Sp-12) is a validated 12-item survey that is commonly used in the palliative care setting. It has 3 subscales (meaning, peace and faith). Scores in each subscale can potentially range from 0-16 and the total scores can range from 0-48. A higher score indicates greater spiritual well-being, better ability to find purpose in life and drawing comfort from spiritual resources.
Healthcare Utilization - Rate of Unplanned Acute Hospital Utilization
Time frame: From Study Enrolment to 3 months Post Enrolment.
The rate of unplanned acute hospital utilization through the emergency department during the study will be collected.
Healthcare utilization - Length of hospital stay
Time frame: From Study Enrolment until Date of Death, up to 3 years.
Data on the length of stay in hospital (bed days) will be collected.
Healthcare utilization - Hospital Bill
Time frame: From Study Enrolment until Date of Death, up to 3 years.
Data on hospital bill size will be collected.
Healthcare utilization - Chemotherapy usage (type)
Time frame: From Study Enrolment until Date of Death, up to 3 years.
Data on the type of chemotherapy used will be collected.
Healthcare utilization - Chemotherapy usage (line)
Time frame: From Study Enrolment until Date of Death, up to 3 years.
Data on the line of chemotherapy (first, second or third or subsequent (fourth and onwards)) will be collected.
Healthcare utilization - Intensive care unit visit
Time frame: From Study Enrolment until Date of Death, up to 3 years.
Data on the number of intensive care unit visits will be collected.
Healthcare utilization - Length of intensive care unit visit
Time frame: From Study Enrolment until Date of Death, up to 3 years.
Data on the length of intensive care unit visits will be collected.
Healthcare utilization - Location of death
Time frame: From Study Enrolment until Date of Death, up to 3 years.
Data on the location of death will be collected.
6 secondary outcomes
Acceptability - Satisfaction
Time frame: 3 months Post Enrolment.
Feasibility - Approach-to-Enrolment Rates
Time frame: From Commencement of Study Recruitment till the End of Recruitment, up to 24 months.
Feasibility - Patient Retention Rate
Time frame: Baseline through Study Completion, estimated as up to 3 years.
Effectiveness - SIC and ACP documentation
Time frame: From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years
Effectiveness - Time spent
Time frame: From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years
Acceptability - Clinician experience
Time frame: At end of intervention period (28th month).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jul 2026.
- Background: PubMed 25330167Bernacki RE, Block SD; American College of Physicians High Value Care Task Force. Communication about serious illness care goals: a review and synthesis of best practices. JAMA Intern Med. 2014 Dec;174(12):1994-2003. doi: 10.1001/jamainternmed.2014.5271.
- Background: PubMed 25202445Nikbakhsh N, Moudi S, Abbasian S, Khafri S. Prevalence of depression and anxiety among cancer patients. Caspian J Intern Med. 2014 Summer;5(3):167-70.
- Background: PubMed 32749931Kumar P, Wixon-Genack J, Kavanagh J, Sanders JJ, Paladino J, O'Connor NR. Serious Illness Conversations With Outpatient Oncology Clinicians: Understanding the Patient Experience. JCO Oncol Pract. 2020 Dec;16(12):e1507-e1515. doi: 10.1200/JOP.19.00765. Epub 2020 Aug 4.
- Background: PubMed 30724693Geerse OP, Lamas DJ, Sanders JJ, Paladino J, Kavanagh J, Henrich NJ, Berendsen AJ, Hiltermann TJN, Fromme EK, Bernacki RE, Block SD. A Qualitative Study of Serious Illness Conversations in Patients with Advanced Cancer. J Palliat Med. 2019 Jul;22(7):773-781. doi: 10.1089/jpm.2018.0487. Epub 2019 Feb 6.
- Background: PubMed 32363775Paladino J, Koritsanszky L, Nisotel L, Neville BA, Miller K, Sanders J, Benjamin E, Fromme E, Block S, Bernacki R. Patient and clinician experience of a serious illness conversation guide in oncology: A descriptive analysis. Cancer Med. 2020 Jul;9(13):4550-4560. doi: 10.1002/cam4.3102. Epub 2020 May 4.
- Background: PubMed 35409844Baxter R, Fromme EK, Sandgren A. Patient Identification for Serious Illness Conversations: A Scoping Review. Int J Environ Res Public Health. 2022 Mar 31;19(7):4162. doi: 10.3390/ijerph19074162.
- Background: PubMed 20713793Sudore RL, Fried TR. Redefining the "planning" in advance care planning: preparing for end-of-life decision making. Ann Intern Med. 2010 Aug 17;153(4):256-61. doi: 10.7326/0003-4819-153-4-201008170-00008.
- BackgroundAgency for integrated care. Advance care planning. Accessed via: aic.sg/Care-Services/Advance-Care-Planning-ACP. Last accessed on February 6th 2026.
- Background: PubMed 35866716Epstein AS, Riley M, Nelson JE, Bernal C, Martin S, Xiao H. Goals of care documentation by medical oncologists and oncology patient end-of-life care outcomes. Cancer. 2022 Sep 15;128(18):3400-3407. doi: 10.1002/cncr.34400. Epub 2022 Jul 22.
- Background: PubMed 35323328Karim S, Levine O, Simon J. The Serious Illness Care Program in Oncology: Evidence, Real-World Implementation and Ongoing Barriers. Curr Oncol. 2022 Mar 2;29(3):1527-1536. doi: 10.3390/curroncol29030128.
- Background: PubMed 37005352Malhotra C, Chaudhry I. Barriers to advance care planning among patients with advanced serious illnesses: A national survey of health-care professionals in Singapore. Palliat Support Care. 2024 Oct;22(5):978-985. doi: 10.1017/S1478951523000214.
- Background: PubMed 22038469Ahluwalia SC, Levin JR, Lorenz KA, Gordon HS. Missed opportunities for advance care planning communication during outpatient clinic visits. J Gen Intern Med. 2012 Apr;27(4):445-51. doi: 10.1007/s11606-011-1917-0. Epub 2011 Oct 25.
- Individual participant dataSharing planned: No
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Benton PT TAM, MSc contact
Shirlyn NEO Hui Shan, MD, PhD study chair
National Cancer Centre, Singapore
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CCC Intervention in people with Cancer, run by National Cancer Centre, Singapore at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Shirlyn NEO Hui Shan, MD, PhD (63065838, shirlyn.neo.h.s@singhealth.com.sg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Communication Quality (time frame: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.). The study lists 12 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07733973, which also lists 37 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2026.